Effect of Astaxanthin Supplementation on Plasma Malondialdehyde Levels and NIHSS of Stroke Patients
Effect of Astaxanthin Supplementation on Plasma Malondialdehyde Levels and NIHSS of Stroke Patients
This is an interventional randomized, controlled trial in analyzing the effects of
 astaxanthin supplementation on plasma malondialdehyde levels and NIHSS of acute ischemic
 stroke patients. According to published studies, it was hypothesized that acute ischemic
 stroke patients who were given astaxanthin would have lower plasma malondialdehyde levels and
 lower NIHSS score compared to the control group.
There were a total of 24 subjects, with 12 subjects in the intervention group and 12 subjects
 in the control group.The participants were divided into an interventional group and a control
 group. The interventional group was given astaxanthin supplementation 2 x 8mg per day for 7
 days, while the control group was given placebo.
Inclusion Criteria:

 -  40-65 years old

 -  Has acute ischemic stroke with an onset of less than 48 hours before hospital
 admission

 -  NIHSS score of less than or equal to 15

 -  Can consume food orally or enterally

 -  Has given their consent to be a participant in the study

 Exclusion Criteria:

 -  Renal failure

 -  Liver failure

 -  Is taking supplements other than his or her main stroke medications

 -  Has taken antioxidant supplements in the last 3 months before stroke onset